Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label multicenter study of SDT-T001 as adjuvant therapy after curative resection in high-risk primary hepatocellular carcinoma
CTR20253756Phase 2Active
- Sponsor
- Nuowei Technology
- Start
- Oct 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SDT-T001 in hepatocellular carcinoma (HCC), sponsored by Nuowei Technology. Started Oct 2025; status: active.
02
Drugs
SDT-T001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20253756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253756.